Ardelyx, AstraZeneca Sign $272M NHE3 Inhibitor Deal
By Staff Reports
Monday, October 8, 2012
Ardelyx Inc.'s goal of landing a partnership in 2012 panned out Monday, with the Fremont, Calif.-based company inking a potential $272.5 million deal with AstraZeneca for rights to its NHE3 inhibitor program, including Phase II-ready compound RDX5791.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.